Rheumatoid arthritis Practice Review – Accessible version of data in this report

Rheumatoid arthritis Practice Review – Accessible version of data in this report

Rheumatoid arthritis Practice Review – Accessible version of data in this report

Date published: 19 October 2020

Log in

Date published: 19 October 2020

How likely is it that you would recommend our site to a friend?

Fig. 2 – Types of csDMARDs dispensed before starting a b/tsDMARD for RA

Fig. 3 – Types of MTX dispensed before starting b/tsDMARD for RA in 2017, 2018 or 2019

Fig. 4 – Choice of first-line b/tsDMARD treatment for patients with RA

Fig. 5 – Number of unique patients dispensed prescriptions for b/tsDMARDs for RA over the years

Fig. 6 – Prescribing of glucocorticoids ≥ 6 months after starting b/tsDMARD treatment for RA

Fig. 7 – Prescribing of opioids for patients also prescribed b/tsDMARDs for RA

Fig. 2 – Types of csDMARDs dispensed before starting a b/tsDMARD for RA

Fig. 3 – Types of MTX dispensed before starting b/tsDMARD for RA in 2017, 2018 or 2019

Fig. 4 – Choice of first-line b/tsDMARD treatment for patients with RA

Fig. 5 – Number of unique patients dispensed prescriptions for b/tsDMARDs for RA over the years

Fig. 6 – Prescribing of glucocorticoids ≥ 6 months after starting b/tsDMARD treatment for RA

Fig. 7 – Prescribing of opioids for patients also prescribed b/tsDMARDs for RA

Our other initiatives:

Feedback

Medicines Line

Adverse Medicine Events Line

Fig. 2 – Types of csDMARDs dispensed before starting a b/tsDMARD for RA

Fig. 3 – Types of MTX dispensed before starting b/tsDMARD for RA in 2017, 2018 or 2019

Fig. 4 – Choice of first-line b/tsDMARD treatment for patients with RA

Fig. 5 – Number of unique patients dispensed prescriptions for b/tsDMARDs for RA over the years

Fig. 6 – Prescribing of glucocorticoids ≥ 6 months after starting b/tsDMARD treatment for RA

Fig. 7 – Prescribing of opioids for patients also prescribed b/tsDMARDs for RA

	Percentage of patients starting b/tsDMARD treatment for RA (by year)
National	2017	2018	2019
Oral MTX only	47	50	38
Subcutaneous MTX only	12	18	15
Oral and subcutaneous MTX	24	21	38
No MTX	18	11	9
NSW/ACT	2017	2018	2019
Oral MTX only	78	81	82
Subcutaneous MTX only	2	1	1
Oral and subcutaneous MTX	4	4	5
No MTX	17	14	12
VIC/TAS	2017	2018	2019
Oral MTX only	77	80	79
Subcutaneous MTX only	3	3	2
Oral and subcutaneous MTX	5	5	7
No MTX	15	12	12
QLD	2017	2018	2019
Oral MTX only	76	80	73
Subcutaneous MTX only	3	2	2
Oral and subcutaneous MTX	4	5	11
No MTX	18	13	14
NT/SA	2017	2018	2019
Oral MTX only	69	71	70
Subcutaneous MTX only	4	3	4
Oral and subcutaneous MTX	6	9	12
No MTX	20	18	15
WA	2017	2018	2019
Oral MTX only	80	75	77
Subcutaneous MTX only	3	3	2
Oral and subcutaneous MTX	3	4	6
No MTX	14	18	14

	Percentage of patients starting b/tsDMARD treatment for RA (1 Jan 2018 to 31 Dec 2019)
	National	NSW/ACT	VIC/TAS	QLD	NT/SA	WA
Adalimumab	24	25	25	21	26	21
Certolizumab	5	5	6	4	4	3
Etanercept	19	19	23	18	15	15
Golimumab	16	16	12	20	15	21
Infliximab	0	0	0	0	0	0
Baricitinib	9	7	11	9	7	8
Tofacitinib	16	16	12	17	21	23
Rituximab	1	1	1	1	1	1
Abatacept	4	4	5	4	5	3
Tocilizumab	6	7	5	6	7	4

	National	2016	2017	2018	2019
TNF inhibitor	Adalimumab	7681	8149	8580	8635
	Certolizumab	1416	1435	1744	2020
	Etanercept	6484	6724	7125	7018
	Golimumab	655	719	2151	2863
	Infliximab	325	318	305	296
JAK inhibitor	Baricitinib	0	0	875	3485
JAK inhibitor	Tofacitinib	3417	4415	5619	6211
B lymphocyte modulator	Rituximab	1114	1201	1184	1158
T lymphocyte modulator	Abatacept	3462	3290	2806	3274
IL-6 inhibitor	Tocilizumab	3302	4494	5132	5415
	NSW/ACT	2016	2017	2018	2019
TNF inhibitor	Adalimumab	2406	2573	2739	2782
	Certolizumab	443	458	555	684
	Etanercept	2319	2374	2452	2352
	Golimumab	204	219	623	849
	Infliximab	98	87	85	84
JAK inhibitor	Baricitinib	0	0	215	957
JAK inhibitor	Tofacitinib	1079	1357	1736	1980
B lymphocyte modulator	Rituximab	267	300	283	273
T lymphocyte modulator	Abatacept	1030	987	798	984
IL-6 inhibitor	Tocilizumab	1002	1424	1688	1797
	VIC/TAS	2016	2017	2018	2019
TNF inhibitor	Adalimumab	2436	2686	2827	2865
	Certolizumab	465	508	632	729
	Etanercept	1632	1826	2117	2185
	Golimumab	162	184	533	741
	Infliximab	79	87	73	72
JAK inhibitor	Baricitinib	0	0	347	1390
	Tofacitinib	1142	1500	1785	1780
B lymphocyte modulator	Rituximab	368	417	384	389
T lymphocyte modulator	Abatacept	943	910	839	1019
IL-6 inhibitor	Tocilizumab	930	1268	1432	1532
	QLD	2016	2017	2018	2019
TNF inhibitor	Adalimumab	1208	1222	1324	1312
	Certolizumab	289	254	290	317
	Etanercept	1004	1042	1089	1090
	Golimumab	156	165	500	627
	Infliximab	54	63	70	70
JAK inhibitor	Baricitinib	0	0	155	502
	Tofacitinib	682	863	1019	1096
B lymphocyte modulator	Rituximab	221	231	247	263
T lymphocyte modulator	Abatacept	586	567	468	531
IL-6 inhibitor	Tocilizumab	620	812	944	1028
	NT/SA	2016	2017	2018	2019
TNF inhibitor	Adalimumab	577	620	653	655
	Certolizumab	55	55	73	104
	Etanercept	485	473	473	479
	Golimumab	51	67	178	202
	Infliximab	22	30	30	28
JAK inhibitor	Baricitinib	0	0	31	210
	Tofacitinib	221	324	435	506
B lymphocyte modulator	Rituximab	67	73	69	66
T lymphocyte modulator	Abatacept	259	275	251	278
IL-6 inhibitor	Tocilizumab	268	376	438	422
	WA	2016	2017	2018	2019
TNF inhibitor	Adalimumab	1115	1106	1111	1073
	Certolizumab	171	170	199	193
	Etanercept	1072	1042	1019	941
	Golimumab	82	87	322	457
	Infliximab	72	51	48	43
JAK inhibitor	Baricitinib	0	0	127	427
	Tofacitinib	301	390	665	875
B lymphocyte modulator	Rituximab	193	183	201	172
T lymphocyte modulator	Abatacept	654	570	458	471
IL-6 inhibitor	Tocilizumab	498	640	661	666

Return to the PBS Practice Review – Rheumatoid arthritis: Quality use of b/tsDMARDs and other medicines

Date published: 19 October 2020

Reasonable care is taken to provide accurate information at the time of creation. This information is not intended as a substitute for medical advice and should not be exclusively relied on to manage or diagnose a medical condition. NPS MedicineWise disclaims all liability (including for negligence) for any loss, damage or injury resulting from reliance on or use of this information. Read our full disclaimer. This website uses cookies. Read our privacy policy.

Percentage of patients starting b/tsDMARD treatment for RA (1 Jan 2018 to 31 Dec 2019)

Leflunomide

Sulfasalazine

Hydroxychloroquine